Merck & Co has announced FDA approval for Keytruda (pembrolizumab) combined with chemotherapy for first-line treatment of ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Recent advancements suggest that a significant competitor to Keytruda, the world’s top-selling cancer therapy, might be emerging.,Keytruda, manufactured b... "Lorem ipsum dolor sit amet, consectetur ...

COPENHAGEN, Denmark I September 16, 2024 I Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing ...

As ever, US pharma giant Merck & Co has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda ...